Bausch + Lomb Acquires Whitecap Biosciences
Bausch + Lomb has announced the acquisition of Whitecap Biosciences, LLC, a biotechnology company developing innovative therapies for glaucoma and geographic atrophy (GA). This acquisition underscores Bausch + Lomb’s commitment to advancing treatments for two significant causes of vision loss.
Promising Therapies for Glaucoma and Geographic Atrophy
Whitecap Biosciences, founded in 2015, has made substantial progress in the development of novel treatments. One key therapy, WB007, is a highly potent alpha-2 adrenergic agonist that has successfully completed Phase 2 clinical trials (NCT04149899) for glaucoma.
•The trial evaluated the safety and IOP-lowering effects of WB007 in adults with primary open-angle glaucoma or ocular hypertension in both eyes.
• Results demonstrated a reduction in intraocular pressure (IOP) from baseline by day 14, signaling significant potential for future therapeutic use.
Leadership Comments
Dr. Yehia Hashad, Chief Medical Officer and EVP of Research & Development at Bausch + Lomb, stated:
“Glaucoma and geographic atrophy are two areas where we believe that dramatic improvement is possible. Whitecap Biosciences’ investigational medicines show real promise when it comes to slowing vision loss and perhaps even improving vision for patients with glaucoma, which would be a long-overdue breakthrough.”
Dr. Scott Whitcup, a founder and former CEO of Whitecap Biosciences, also commented:
“Glaucoma and geographic atrophy can cause severe vision loss, with many patients experiencing progressive deterioration. By joining a global leader like Bausch + Lomb, we hope Whitecap’s assets will be developed into effective treatments that improve visual outcomes for patients.”
Looking Ahead
Bausch + Lomb has announced plans for additional clinical trials to further evaluate therapies for both glaucoma and geographic atrophy, aiming to deliver breakthrough treatments that improve patient outcomes and address significant unmet needs.
This acquisition marks an exciting milestone in the development of innovative therapies for vision-threatening conditions and reflects Bausch + Lomb’s dedication to advancing ophthalmic care globally.
